SCEMBLIX Drug Patent Profile

Which patents cover Scemblix, and when can generic versions of Scemblix launch?

Scemblix is a drug marketed by Novartis and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in SCEMBLIX is asciminib hydrochloride. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the asciminib hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Scemblix

Scemblix was eligible for patent challenges on October 29, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 14, 2040. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

Summary for SCEMBLIX

US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	4
Drug Prices:	Drug price information for SCEMBLIX
What excipients (inactive ingredients) are in SCEMBLIX?	SCEMBLIX excipients list
DailyMed Link:	SCEMBLIX at DailyMed

See drug prices for SCEMBLIX

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SCEMBLIX

Constraining patent/regulatory exclusivity:

11,407,735

NDA:

215358

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for SCEMBLIX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SCEMBLIX	Tablets	asciminib hydrochloride	100 mg	215358	5	2025-11-13

US Patents and Regulatory Information for SCEMBLIX

SCEMBLIX is protected by four US patents and nine FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 11,407,735.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	SCEMBLIX	asciminib hydrochloride	TABLET;ORAL	215358-003	Apr 18, 2024		RX	Yes	Yes	11,407,735			Y
Novartis	SCEMBLIX	asciminib hydrochloride	TABLET;ORAL	215358-003	Apr 18, 2024		RX	Yes	Yes
Novartis	SCEMBLIX	asciminib hydrochloride	TABLET;ORAL	215358-001	Oct 29, 2021		RX	Yes	No	12,252,479
Novartis	SCEMBLIX	asciminib hydrochloride	TABLET;ORAL	215358-001	Oct 29, 2021		RX	Yes	No
Novartis	SCEMBLIX	asciminib hydrochloride	TABLET;ORAL	215358-001	Oct 29, 2021		RX	Yes	No	11,407,735			Y

International Patents for SCEMBLIX

When does loss-of-exclusivity occur for SCEMBLIX?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Croatia

Denmark

European Patent Office

Finland

Israel

Japan

Lithuania

Mexico

Poland

Portugal

Serbia

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SCEMBLIX around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2020276701
Brazil	112021022712
Canada	3139812
Chile	2021003011
China	114144232

Supplementary Protection Certificates for SCEMBLIX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2861579	301201	Netherlands		PRODUCT NAME: ASCIMINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS ASCIMINIBHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/22/1670 20220826
2861579	CR 2022 00046	Denmark		PRODUCT NAME: ASCIMINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SASOM ASCIMINIB HYDROKLORID; REG. NO/DATE: EU/1/22/1670 20220826
2861579	PA2022523	Lithuania		PRODUCT NAME: ASCIMINIBAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA, TOKIA KAIP ASCIMINIBO HIDROCHLORIDAS; REGISTRATION NO/DATE: EU/1/22/1670 20220825
2861579	2022C/548	Belgium		PRODUCT NAME: ASCIMINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN, ZOALS ASCIMINIB HYDROCHLORIDE; AUTHORISATION NUMBER AND DATE: EU/1/22/1670 20220826
2861579	122022000072	Germany		PRODUCT NAME: ASCIMINIB ODER EIN PHARMAZEUTISCH UNBEDENKLICHES SALZ DAVON, WIE ZUM BEISPIEL ASCIMINIBHYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1670 20220825

SCLAIX (scemblix, asciminib) Market Dynamics and Financial Trajectory: Pricing, Uptake, Revenue Drivers, Competitive Pressure, and Patent-Linked Risk

Last updated: June 10, 2026

Sceemblix (asciminib) is a niche, high-cost chronic-therapy oncology drug anchored on CML and the ABL myristoyl pocket mechanism. Commercial momentum is constrained by (1) a limited eligible population defined by kinase-genotype and prior treatment history, (2) payer coverage and high net-price pressure common to oral oncology agents, and (3) competition from earlier-line TKIs and mechanism-diverse later entrants in CML sequencing. The near-to-mid-term financial trajectory is dominated by conversion from second-line and later use into durable chronic treatment, attrition to discontinuation, and share gains tied to guideline placement versus TKI rescue strategies.

How has scemblix performed commercially since launch?

Answer: Revenue trajectory depends on penetration within the ABL myristoyl pocket inhibitor-treated segment and on sustained retention on therapy. Uptake is typically strongest in regions and lines where asciminib has the cleanest benefit narrative versus ponatinib or other TKI strategies after failure of prior therapy.

Key commercial levers

• Line-of-therapy placement: Growth is sensitive to how clinicians position asciminib after prior TKI failure, particularly where molecular response durability is valued versus chronic toxicity trade-offs.
• Treatment duration and adherence: Because CML therapy is long duration, net revenue is more retention-driven than one-off dosing.
• Center-of-excellence prescribing patterns: In practice, uptake often concentrates in academic and large oncology networks with CML expertise.
• Payer and formulary path: High list prices require payer support; formulary tiering and PA (prior authorization) can delay conversions.

Demand signal indicators used by investors and pharma finance teams

• New starts per quarter (by line): reflects diagnosis and switching patterns.
• Persistence at 3, 6, 12 months: retention is a primary determinant of revenue.
• Time on therapy after response: correlates with net sales stability.
• Geographic share: differences in reimbursement rules move regional revenue trajectories materially.

What market does scemblix address in CML, and how does that shape sales?

Answer: Asciminib targets CML via the ABL myristoyl pocket, narrowing the addressable market to patients likely to benefit based on prior TKI exposure and treatment eligibility.

Indication scope and addressable population mechanics

• CML patient selection: Eligibility is determined by CML phase and prior TKI treatment history, plus ongoing molecular monitoring practices.
• Mutation and resistance context: Mechanism targeting can support switching after resistance or intolerance, but does not erase the need for prior TKI exposure qualification.
• Sequencing dynamics: In CML, clinicians often reserve later-line options for patients with limited alternatives; that increases the “share-fighting” role of safety and response depth.

Market sizing logic for financial planning

For revenue modeling, teams typically treat asciminib as:

• A share-of-switching market rather than a first-line bulk market.
• A duration-based chronic revenue stream after conversion into treatment.

What pricing and reimbursement dynamics affect scemblix net sales?

Answer: As an oral oncology drug, asciminib is priced at a premium and is exposed to standard net-price compression channels: rebates, discounts, and formulary step therapy in commercial markets, with government and statutory reimbursement rules setting additional regional differences.

Net-price risk factors

• Gross-to-net spread: rebates tied to outcomes, volume, or formulary position.
• Use restrictions: PA criteria can limit new starts even when clinical demand exists.
• Switching vs new patient starts: net sales scale depends on switching patterns from existing TKIs rather than only incident CML.

Investor-style implications for cash flow

• Margin variability is driven by rebate intensity and payer contracting terms, not manufacturing cost alone.
• ARPU (average revenue per treated patient) is sensitive to dose continuity and discontinuation rates.

How does scemblix compare with ponatinib and other CML TKIs on uptake drivers?

Answer: Uptake is strongest where asciminib offers a clear differentiation versus TKI rescue strategies, typically in cases where tolerability, response durability, or safety profile shifts prescribing behavior.

Competitive axes that move share

• Mechanism differentiation: ABL myristoyl pocket inhibition competes directly with clinicians’ strategy for TKI resistance management.
• Safety and discontinuation risk: Reduced discontinuation improves retention and supports revenue stability.
• Response durability: Deeper or more durable responses lower the probability of switching away, supporting chronic revenue.
• Real-world prescribing inertia: Many patients start on standard TKIs; asciminib must win at switch points.

Practical market dynamics

• Competitive pressure is not only drug choice but also sequencing frameworks: guidelines, payer coverage, and physician experience determine when asciminib is selected.

What generic or biosimilar entry risks exist for scemblix?

Answer: For small-molecule drugs like asciminib, generic risk is driven by patent estate strength, exclusivity, and regulatory pathway timing. No biosimilar risk applies.

Entry pathways to monitor

• ANDA (generic small-molecule): typically tied to patent challenges and market exclusivity windows.
• Paragraph IV litigation: can accelerate generic entry post-expiration if settlement terms allow “early” or “at-risk” entry.

How to think about “financial trajectory” under patent expiry

• Upside: sustained revenue until last relevant composition-of-matter and method-of-use barriers clear.
• Downside: post-expiration price erosion can cause a steep net sales drop in oncology niche drugs when conversion volume is high.

What patents protect scemblix and when do they expire?

Answer: Patent-led exclusivity is the primary determinant of the post-launch revenue ceiling and the generic entry timing risk profile.

Patent estate categories that typically matter for launch drugs

• Composition of matter: usually the strongest barrier for generics.
• Formulation patents: can extend market protection for specific dosage forms or release profiles.
• Method-of-use patents: can restrict labeled uses and drive narrower generic challenges.
• Manufacturing/process patents: can block generic process design if not designed around.

Expiration timeline mechanics

Financial planning uses:

• Earliest “hard” expiration (composition of matter)
• Latest “soft” expiration (method-of-use/formulation)
• Any pediatric exclusivity or regulatory exclusivity extensions if applicable
• “Orange Book” listed patent terms that map to FDA reference listed drug protection

What is the FDA regulatory status of scemblix and how does it affect sales velocity?

Answer: Sales velocity depends on label scope and how quickly FDA approvals enable broader line expansion. Wider label indications generally raise the accessible prescribing population, though payer coverage often lags.

Approval timing dynamics

• Label expansion events typically produce step changes in starts.
• Safety and efficacy updates can shift prescriber comfort and guideline positioning.

Pathway and labeling effects

• Broader indication language reduces administrative friction for PAs.
• Clear clinical endpoints can improve reimbursement predictability.

What litigation and settlement activity could change scemblix’s competitive threat?

Answer: Patent litigation and settlement terms can materially change the timing of generic market entry and therefore the revenue decay curve.

What to track for financial impact

• Filed Paragraph IV notices and the associated Orange Book patents.
• Court schedules that can delay or expedite trial.
• Settlement dates and “date-certain” entry commitments.
• Scope of any permitted generic marketing (label carve-outs can preserve brand share).

How many competitors are targeting asciminib’s segment, and what do they do differently?

Answer: The competitive set includes (1) mechanism-diverse CML TKIs in earlier lines and rescue settings and (2) later-line targeted approaches that compete for switch decisions.

Competitive landscape structure used in models

• Therapy-level competitors: TKIs with established sequencing roles.
• Mechanism-level competitors: drugs aimed at different resistance biology.
• Administration and tolerability competitors: agents with improved safety profiles can win where discontinuation risk drives physician behavior.

Key differentiators that translate into commercial share

• A response depth narrative that supports durable retention
• A tolerability profile that reduces discontinuation and switching
• Label breadth that reduces coverage barriers

Which geographies are likely to drive scemblix growth fastest?

Answer: Growth typically concentrates in markets where reimbursement is less restrictive and where CML treatment centers adopt newer targeted options quickly.

Geographic drivers

• Reimbursement frameworks and PA intensity
• National formularies and guideline-adjacent use criteria
• Specialty pharmacy distribution models and hospital procurement contracting
• Time-to-access after label updates

What is the financial trajectory outlook for scemblix over the next 3–5 years?

Answer: The base case typically assumes continued growth as an incremental share winner in a defined CML segment, followed by a deceleration as penetration saturates and competition in sequencing intensifies. The downside case is accelerated decline around patent cliffs or intensifying generics-related litigation outcomes; the upside case is label expansion, stronger retention, and payer coverage improvements.

Revenue model components

• Treated patient count growth (new starts and switches)
• Average duration (persistence)
• Net pricing evolution (rebate intensity and payer contracting)
• Mix shifts by line-of-therapy and geography
• Costs and margin sensitivity to contracting structures

What would change the trajectory

• Rapid payer broadening after outcomes evidence
• Clinical guideline changes that move asciminib earlier in sequencing
• Patent litigation outcomes that either delay generic entry or change settlement dates

Key Takeaways

• Asciminib’s financial trajectory is driven by conversion into a defined, high-value CML segment and by chronic retention on therapy more than by broad first-line adoption.
• Net sales growth is constrained by payer barriers and sequencing dynamics against established TKIs.
• Competitive share is most sensitive to retention (discontinuation risk) and depth/durability of response claims that influence switch decisions.
• Patent estate strength and Orange Book-listed barriers are the critical determinants of generic entry timing risk and the shape of revenue after the exclusivity window.
• The next 3–5 years hinge on label breadth and payer access, with material downside risk if patent expiry or settlement terms accelerate generic competition.

FAQs

1. How do prior TKI resistance patterns influence asciminib switching demand?
2. What reimbursement levers most affect net pricing for oral oncology drugs like scemblix?
3. How does line-of-therapy sequencing in CML change the uptake curve of asciminib?
4. What Orange Book patent categories typically create the biggest barriers to generic entry for small-molecule oncology drugs?
5. What persistence assumptions are most important for forecasting scemblix revenue in long-duration CML therapy?

References

1. [No sources were provided or identified in the prompt, and no drug-specific regulatory/patent dataset links were supplied.]